Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.72

€0.72

6.900%
0.05
6.900%
-
 
28.03.24 / Tradegate WKN: A14VXX / Name: Seres / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Seres Therapeutics Inc Stock

A very strong showing by Seres Therapeutics Inc today, with an increase of €0.050 (6.900%) compared to yesterday's price.
So far the community has only identified positive things for Seres Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Seres Therapeutics Inc in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Seres Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Seres Therapeutics Inc 6.900% -2.041% -32.710% -85.940% -45.038% -95.556% -
Salarius Pharmaceuticals Inc. 2.420% -18.824% -22.617% -76.389% -25.405% -98.665% -99.992%
Ardelyx Inc. -1.160% -6.371% -22.654% 73.980% 16.955% 25.791% -
Evolus Inc -0.770% 2.362% -2.985% 66.667% 39.037% 31.287% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-24

Overall, Seres, a company operating in the biotechnology and medical research industry, demonstrates mixed financials. While some aspects of the company's financial health appear promising, other elements suggest a need for improvement. In order to fully comprehend the financial standing of Seres, it is crucial to dive deeper into the details and evaluate the merits and demerits associated with the company's financial performance.

Strong Cash Position: Seres boasts a robust cash balance, with $163,030,000 reported on its 2022-12-31 balance sheet. This substantial cash position grants the company some degree of financial stability and flexibility, which is especially critical in the biotechnology and medical research sector, where the need to fund research and development initiatives is ongoing.

Increasing Revenue: An examination of Seres' income statements reveals a trend of increasing revenue. This indicates a potential for growth, which is a positive sign for investors.